Resmed (RMD) Stock
Sleep apnea device giant with digital health services. Here's the price, business snapshot, and what's worth knowing about Resmed in July 2026.
ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions — a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice — consider your personal circumstances and tolerance for volatility before investing.
Why It’s Moving
ResMed Shares Gain Momentum as Analysts Shift to a Confident Buy Rating Amid Strong 2026 Earnings Outlook
- Analysts highlighted a significant consensus price target increase to approximately $290, reflecting a 13% revision in earnings estimates that underscores stronger-than-expected product demand.
- The upgrade to a 'Moderate Buy' consensus, driven by nine 'Strong Buy' ratings from a panel of 19 analysts, indicates growing institutional confidence in ResMed's long-term growth trajectory.
- Earnings data showing a 13% rise in diluted EPS for the fiscal year ending June 2026 has reinforced the narrative that the company is successfully navigating macroeconomic pressures while expanding its market share.
ResMed Shares Gain Momentum as Analysts Shift to a Confident Buy Rating Amid Strong 2026 Earnings Outlook
- Analysts highlighted a significant consensus price target increase to approximately $290, reflecting a 13% revision in earnings estimates that underscores stronger-than-expected product demand.
- The upgrade to a 'Moderate Buy' consensus, driven by nine 'Strong Buy' ratings from a panel of 19 analysts, indicates growing institutional confidence in ResMed's long-term growth trajectory.
- Earnings data showing a 13% rise in diluted EPS for the fiscal year ending June 2026 has reinforced the narrative that the company is successfully navigating macroeconomic pressures while expanding its market share.
When is the next earnings date for RESMED INC (RMD)?
ResMed's next earnings report is expected to be released on July 30, 2026, covering the fourth quarter of fiscal year 2026. This date aligns with the company's historical reporting pattern, though the company has not yet formally confirmed the specific publication time. Investors should anticipate key financial metrics and outlook updates during this announcement to assess the company's performance over the quarter. Please note that this is an estimated date based on prior schedules and does not constitute a confirmed financial recommendation or price target.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ResMed's stock, indicating expected growth towards a higher target price.
Financial Health
ResMed is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
ResMed's dividend yield of 0.92% is below average, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring RMD
Wearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: 12 September 2025
Explore BasketRest & Recharge
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Published: 17 June 2025
Explore BasketRest & Recovery
This carefully curated collection features companies at the forefront of sleep science and recovery technology. These stocks represent a growing market where innovation meets wellness, selected by professional analysts tracking the expanding health optimization trend.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.
Global patient base
An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.
Connected‑care push
Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
